Clinical trials: Healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - Results from two randomized controlled studies

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 7, 2009, Pages 731-741

  Sharma, P ^a   Shaheen, N J ^b   Perez, M C ^c   Pilmer, B L ^c   Lee, M ^d   Atkinson, S N ^c   Peura, D ^e  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c TAKEDA PHARMACEUTICALS   (United States)

^d TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ATTAPULGITE; DEXLANSOPRAZOLE; LANSOPRAZOLE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY SPASM; CRUDE RATE ANALYSIS; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; FEMALE; HEALING; HEARTBURN; HUMAN; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONCARDIAC CHEST PAIN; PARALYSIS; PARAMETER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESOPHAGITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 61849139946     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.03933.x     Document Type: Article

References (45)

1. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 100 : 190 200.
2. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2004 4 : CD003245.
3. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 2005 22 : 79 94.
4. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998 10 : 119 24.
5. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005 54 : 710 7.
6. Locke GR 3rd., Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997 112 : 1448 56.
7. Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008 27 : 473 82.
8. Robinson M, Earnest D, Rodriguez-Stanley S, et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med 1998 158 : 2373 6.
9. Nocon M, Labenz J, Jaspersen D, et al. Long-term treatment of patients with gastro-oesophageal reflux disease in routine care - results from the ProGERD study. Aliment Pharmacol Ther 2007 25 : 715 22.
10. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002 97 : 575 83.
11. Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther 2005 22 (Suppl. 3 10 9.
12. Kaynard A, Flora K. Gastroesophageal reflux disease. Control of symptoms, prevention of complications. Postgrad Med 2001 110 : 42 4, 7 8, 51 3.
13. Fitzgerald RC. Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation? Gut 2005 54 (Suppl. 1 i21 6.
14. Katsuki H, Yagi H, Arimori K, et al. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res 1996 13 : 611 5.
15. Zhang W, Wu J, Atkinson S. Pharmacokinetics, pharmacodynamics, and safety evaluation of a single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified-release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole in healthy subjects. Gastroenterology 2007 132 (Suppl. 52 487A (abstract).
16. Chey W, Huang B, Jackson R. Lansoprazole and esomeprazole in symptomatic GERD. A double-blind, randomised, multicentre trial in 3000 patients confirms comparable symptom relief. Clin Drug Invest 2003 23 : 69 84.
17. Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003 18 : 587 94.
18. Miner P Jr., Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002 97 : 1332 9.
19. Robinson M, Campbell DR, Sontag S, Sabesin SM. Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor. Dig Dis Sci 1995 40 : 590 7.
20. Robinson M, Sahba B, Avner D, Jhala N, Greski-Rose PA, Jennings DE. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. Aliment Pharmacol Ther 1995 9 : 25 31.
21. Freston JW, Rose PA, Heller CA, Haber M, Jennings D. Safety profile of lansoprazole: the US clinical trial experience. Drug Saf 1999 20 : 195 205.
22. Ligumsky M, Lysy J, Siguencia G, Friedlander Y. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol 2001 33 : 32 5.
23. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000 14 : 1249 58.
24. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001 96 : 656 65.
25. Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005 21 : 739 46.
26. Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000 95 : 3071 80.
27. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 1999 13 : 49 57.
28. Peura DA, Lee C, Siepman N, Kovacs TO. Long-term efficacy of symptom-based, titrated dose lansoprazole in preventing relapse of erosive reflux esophagitis in subjects with a recent history of erosive reflux esophagitis. Gastroenterology 2005 128 (Suppl. 2 527 8 (abstract).
29. ® (esomeprazole magnesium). Full Prescribing Information. Wilmington, DE : AstraZeneca LP, 2008.
30. ® (Omeprazole). Full Prescribing Information. Wilmington, DE : Astra Zeneca LP, 2008.
31. ® (rabeprazole sodium). Full Prescribing Information. Tokyo, Japan : Eisai Co, Ltd, 2008.
32. ® (pantoprazole sodium). Full Prescribing Information. Philadelphia, PA : Wyeth Pharmaceuticals, Inc., 2008.
33. Bergstrand R, Grind M, Nyberg G, Olafsson B. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standard breakfast. Clin Drug Invest 1995 9 : 67 71.
34. Delhotal-Landes B, Cournot A, Vermerie N, Dellatolas F, Benoiot M, Flouvat B. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 1991 3 : 315 20.
35. Prevacid® (lansoprazole). Full Prescribing Information. Lake Forest, IL : TAP Pharmaceutical Products, Inc., 2008.
36. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000 14 : 1267 72.
37. Sostek MB, Chen Y, Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol 2007 64 : 386 90.
38. Persson K. When do ulcer patients take their acid inhibiting medication? Hässle Inf 1993 7 : 19 23.
39. Lee RD, Vakily M, Wu J, Atkinson S. The effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR (Modified Release): evidence for dosing flexibility. Am J Gastroenterol 2007 102 (S2 S145 (abstract).
40. Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999 49 : 463 4.
41. The Gallup Organization. Gallup Study of Consumers' Use of Stomach Relief Products. Princeton, NJ : The Gallup Organization, 2000.
42. Vakil NB. Review article: gastro-oesophageal reflux disease and Helicobacter pylori infection. Aliment Pharmacol Ther 2002 16 (Suppl. 1 47 51.
43. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999 117 : 11 6.
44. Vakil NB, Traxler BM, Levine D. Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. Am J Gastroenterol 2004 99 : 1437 41.
45. Castro Fernandez M, Garcia Diaz E, Larraona JL, et al. Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori. Rev Esp Enferm Dig 2006 98 : 170 9.